A Synthetic Trivalent Hapten that Aggregates anti-2,4-DNP IgG into Bicyclic Trimers
摘要:
This paper describes the synthesis of the trivalent hapten molecule 1, containing three 2,4-dinitrophenyl (2,4-DNP) groups, and the use of this molecule to aggregate three molecules of anti-2,4-DNP IgG into a complex with 3:2 stoichiometry (IgG(3)1(2)). The equilibrium product IgG(3)1(2) was generated in similar to 90% yield upon mixing IgG and 1; during incubation, thermodynamically unstable, high-molecular-weight aggregates (> 10(4) nm in diameter) form first and convert subsequently to IgG(3)1(2). The thermodynamics and the kinetics of the formation of aggregates were studied using size-exclusion high-performance liquid chromatography (SE-HPLC), dynamic light scattering (DLS), and analytical ultracentrifugation (AUC). An analytical model based on multiple species in equilibrium was developed and used to interpret the SE-HPLC data. The aggregate IgG(3)1(2) was more stable thermodynamically and kinetically than monomeric aggregates of this IgG with monomeric derivatives of 2,4-DNP; this stability suggests potential applications of these aggregates in biotechnology.
Die vorliegende Erfindung betrifft ein kosmetisches Mittel, welches im wesentlichen aus einem peptidischen Linker und mindestens einem damit kovalent verbundenem kosmetischen Wirkstoff besteht.
[EN] NANOPARTICLE CONJUGATES AND METHOD OF PRODUCTION THEREOF<br/>[FR] CONJUGATS DE NANOPARTICULES ET LEUR PROCEDE DE PRODUCTION
申请人:UNIV LIVERPOOL
公开号:WO2004047870A1
公开(公告)日:2004-06-10
The present invention provides a method for the preparation of nanoparticle conjugates comprising: protocols for synthesizing intermediate product molecules by introducing known numbers of two or more substituents into a flexible hydrophilic polymer, where one substituent is capable, optionally after deprotection, of binding to a nanoparticle, and where the other substituents are capable of participating in analytical or other applications; protocols for contacting the intermediate product molecules with nanoparticles for a period of time and under conditions effective to allow the binding of a known number of the intermediate product molecules to each nanoparticle to provide the nanoparticle conjugate.